ÂÜÀòÂÒÂ×

Jim Glasheen

Board Member at Autobahn Labs

Over the past 25 years, Jim led efforts to translate biomedical innovations into broader societal impact as an academic, a strategic consultant, a venture investor, and an executive. Jim is a co-founder and President / CBO of Clade Therapeutics. Previously, he was co-founder and founding President and CEO of Atalanta Therapeutics, Executive Vice Chancellor at UMASS Medical School, co-lead of Life Science Practice at Technology Partners Venture Capital, and a leader within the Pharmaceutical and Medical Products practice at McKinsey & Company. His training includes a post-doctoral fellowship at University of California, Berkeley, a PhD from Harvard University, a Deutscher Akademischer Austauschdienst Fellowship at Universität des Saarlandes and a BS from Duke University.